Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
61-80 of 604 trials

Staphylococcus aureus Bacteremia: SNAP Trial

We are testing various treatment options for patients with Staphylococcus aureus bacteremia to see how they impact survival and other health outcomes. This study aims to improve care for those affected by this serious infection.

Staphylococcus aureus Bacteremia3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesInfectious DiseasesInternal Medicine

Dementia Care: Benefits of Amyloid PET Imaging

We are exploring how amyloid PET imaging may improve care for people with dementia compared to standard diagnostic methods. This study aims to show its impact on important health outcomes.

Dementia>2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteNeurologyPsychiatry

Relatlimab and Nivolumab for Young Lymphoma Patients

We are studying a combination of two medications for children and young adults with recurrent or hard-to-treat Hodgkin and Non-Hodgkin lymphoma. The goal is to understand their safety and how well they may work.

Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncologyPediatrics

Gastroparesis: Tradipitant Safety Study

We are evaluating the safety of a new medication, tradipitant, for patients with gastroparesis. The study also looks at how well it may help reduce symptoms and improve quality of life.

Gastroparesis3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyGastroenterology

Major Depressive Disorder: Lumateperone Study

We are testing lumateperone as an additional treatment for people with major depressive disorder who aren't responding well to their current antidepressants. The study will help us understand its effectiveness and safety.

Major Depressive Disorder≤3 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePsychiatry

Mild Male Factor Infertility: PKB171 Gel Study

We are testing a new intravaginal gel to see if it helps couples with mild male factor infertility achieve pregnancy. The study compares the gel's effects to a placebo over three treatment cycles.

Male Infertility6-12 monthsEfficacy phase (II)Confirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteGynecology and ObstetricsUrology

Geographic Atrophy: Tinlarebant Treatment Study

We are exploring whether Tinlarebant can slow the growth of lesions in people with geographic atrophy and improve their vision. This study compares the new treatment to a placebo to assess its effectiveness.

Geographic Atrophy>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesOphthalmology

Graft-versus-Host Disease: MC0518 Treatment for Kids

We are studying a new treatment called MC0518 for children with steroid-refractory acute graft-versus-host disease after stem cell transplant. The goal is to see if it works better than the best available therapy.

Steroid Refractory Acute Graft Versus Host Disease>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematologyInfectious Diseases

LiBRA: Lithium for Cognitive Protection After Brain Radiotherapy

We are studying whether lithium can help prevent cognitive problems in children who received brain radiotherapy for cancer. The trial also looks at overall quality of life and safety of the treatment.

Brain Tumor3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesNeurologyOncology

Primary Biliary Cholangitis: Bezafibrate Treatments

We are studying the effects of two doses of bezafibrate in patients with primary biliary cholangitis who aren't responding well to current therapy. The goal is to see if these treatments can improve symptoms and liver health.

Primary Biliary Cholangitis>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessStandard MedicinesGastroenterologyHepatology

Nicotinamide for Liver Fibrosis in Type 2 Diabetes

We are studying whether nicotinamide can help slow liver fibrosis in people with type 2 diabetes. The trial will also assess safety and other health factors related to obesity.

Hepatic Fibrosis>2 yearsEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesDiabetologyEndocrinologyHepatology

Prostate Cancer: AZD5305 Treatment Study

We are studying whether AZD5305, combined with standard hormonal treatments, can improve outcomes for men with metastatic castration-sensitive prostate cancer. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Eosinophilic Granulomatosis With Polyangiitis: NS-229 Study

We are testing a new treatment, NS-229, to see if it helps patients with Eosinophilic Granulomatosis With Polyangiitis achieve remission better than a placebo. The study will also look at any side effects and the time until symptoms worsen.

Eosinophilic Granulomatosis with Polyangiitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Advanced Solid Tumors: Rezatapopt Treatment Study

We are evaluating a new treatment for patients with advanced solid tumors that have a specific genetic mutation. The study aims to understand its effectiveness and safety, as well as how it affects quality of life.

Locally Advanced or Metastatic Solid Tumors with TP53 Y220C MutationSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Montelukast for Mild-Moderate Parkinson’s Disease

We are studying whether Montelukast can slow disease progression in people with mild to moderate Parkinson’s disease. The trial also examines its effects on symptoms and potential side effects.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Pulmonary Arterial Hypertension: Triple Therapy Study

We are investigating whether a new combination of treatments, including an injectable medication, improves health outcomes for patients with pulmonary arterial hypertension. This study compares it to a standard oral treatment to see which is more effective.

Pulmonary Arterial Hypertension6-12 monthsConfirmation phase (III)Monitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Atopic Dermatitis: Methotrexate Injection Study

We are testing whether subcutaneous methotrexate can improve skin symptoms in adults with moderate to severe atopic dermatitis compared to a placebo. The study also examines safety and quality of life for participants.

Moderate to Severe Atopic Dermatitis3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesAllergologyDermatology

Type 2 Diabetes: Finerenone and SGLT2 Inhibitors

We are studying the effects of a new treatment combining finerenone with SGLT2 inhibitors for people with type 2 diabetes. The goal is to see if this combination improves heart and kidney health.

Type 2 DiabetesChronic Kidney Disease>2 yearsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementCardiologyEndocrinologyNephrology

Rosuvastatin for Preventing Venous Thromboembolism Recurrence

We are studying whether generic rosuvastatin can help prevent further blood clots in patients with a history of venous thromboembolism. We will also look at its safety and effects on bleeding and other vascular events.

Deep Vein ThrombosisPulmonary EmbolismVenous Thromboembolism>2 yearsConfirmation phase (III)6-10 visitsInvestigational MedicinesPartially RemoteCardiologyHematology

Spinal Muscular Atrophy: Risdiplam Treatment Study

We are studying the effectiveness and safety of risdiplam in children with spinal muscular atrophy who have received gene therapy. This research aims to see if early treatment can improve their condition.

Spinal Muscular Atrophy>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyPediatrics